My name is Archibald James Mixson, and in 1974, I graduated from Vanderbilt University with a major in mathematics. I earned an M.D. in 1979 and then did an Internal Medicine residency at Emory University in Atlanta, Ga. After finishing a staff fellowship in NCI to study intermediary metabolism, I did an endocrinology fellowship with the NIDDK. I am board certified in Internal Medicine and Endocrinology. In 1986, I joined the pathology department at the University of Maryland School of Medicine and have been a full professor since 2013. My laboratory initially focused on the non-viral delivery of anti-angiogenic “nucleic acids” utilizing in vitro or in vivo models. Currently, research in my laboratory is directed at developing novel histidine-rich peptides as nucleic acid carriers and antifungal agents. Significant accomplishments in the nucleic acid delivery field in our laboratory include the first group to deliver a tumor suppressor gene (p53) intravenously and reduce tumor size, one of the earliest groups to demonstrate that anti-angiogenesis was an essential mechanism for the bystander effect of p53 gene therapy and the first group to deliver systemically genes encoding anti-angiogenic peptides. During the last two decades, our laboratory has developed histidine-rich peptides as carriers of nucleic acids. From these studies, I have been awarded several patents on gene therapy, anti-angiogenesis, and drug delivery carriers.